Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 3/20 | 0.32 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945211 | 0.82 | MAOB (0.33) | MAOB | |
| SCHEMBL21944761 | 0.82 | NOTUM (0.35) | — | |
| SCHEMBL21945709 | 0.79 | MPL (0.42) | KMO | |
| SCHEMBL21945217 | 0.79 | NOTUM (0.47) | MAPK14ABL1 | |
| SCHEMBL21944755 | 0.78 | KDM1A (0.32) | MAOBPSD | |
| SCHEMBL21945244 | 0.78 | POLB (0.33) | — | |
| SCHEMBL21944765 | 0.76 | MAOB (0.34) | MAOB | |
| SCHEMBL21945116 | 0.76 | POLB (0.31) | — | |
| SCHEMBL21945209 | 0.74 | MAOB (0.39) | MAPK14MAOBABL1 | |
| SCHEMBL21945216 | 0.74 | MAOB (0.39) | MAPK14MAOBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAPK14 663/4885SIRT1 146/4885EGLN2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.